Vol. 2, Issue 1 (2013)
Heart Failure Treatment In Patients With Recurrent Myocardial Infarction
160 patients with heart failure classes II and III with recurrent myocardial infarction have undergone treatment by means of cardioprotector - isosorbide mononitrate – mononitrosid and metabolitotropic drug 5-lipoxygenase inhibitor corvitin/quercetin. All the suggested treatment regimens of heart failure in patients with recurrent myocardial infarction had high antagonistic effectiveness, resulted in the decrease of blood pressure, pulse pressure, improved structural and functional characteristics of the myocardium (including the increase in ejection fraction (EF), and significant decrease of left ventricular end-diastolic dimension (LVEDd), end-diastolic volume (EDV), left ventricular mass index (LVMI), reduced NT-proBNP levels, Total NO and improved heart rate variability.
How to cite this article:
Ruslana Denina. Heart Failure Treatment In Patients With Recurrent Myocardial Infarction. The Pharma Innovation Journal. 2013; 2(1): 30-35.